GSK和辉瑞在RSV疫苗市场竞争，伴随新批准和数据出现
NoahAI News ·
辉瑞的Abrysvo已获得FDA批准，用于18至59岁具有较高风险罹患由RSV引起的下呼吸道疾病（LRTD）的成年人，标志着这是首个为这一年轻群体批准的RSV疫苗[2][3][5]。此次批准从早期对60岁以上人群和孕妇的批准扩展而来，使辉瑞能够增强其市场存在，对抗如GSK的Arexvy等竞争对手[1][3]。这一决策得到了Phase 3 MONeT试验的支持，该试验展示了高风险人群中的强烈免疫反应，为在RSV疫苗市场进一步推广奠定了基础[4][5]。
References
- GSK answers Pfizer's RSV approval with data targeting matching nod in younger adults
- With expanded FDA nod for RSV shot Abrysvo, Pfizer gains edge on GSK's Arexvy. But will it amount to much?
- Pfizer Wins FDA Approval of RSV Vaccine for Broader Adult Population
- Pfizer’s RSV vaccine cleared by FDA for use in some younger adults
- U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease